Legend Biotech (LEGN) Interest Coverage Ratio (2019 - 2026)
Legend Biotech's (LEGN) quarterly Interest Coverage Ratio came in at 9.05 in Q1 2026, up 10.68% YoY from 8.18 in Q1 2025, and down 352.79% on a QoQ basis from 3.58 in Q4 2025.
Legend Biotech (LEGN) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Interest Coverage Ratio data on file, last reported at 9.05 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 10.68% year-over-year to 9.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.41 (down 107.2% YoY) and the FY2025 annual result came in at 6.38, up 144.55% from the prior year.
- Interest Coverage Ratio slipped to 9.05 in Q1 2026, from 3.58 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 32.47 in Q1 2024 to a low of 13648055.74 in Q4 2023.
- A 5-year average of 802831.98 and a median of 6.72 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 2232.99% — and 2023, when it tumbled 59178890.36%.
- Tracing LEGN's Interest Coverage Ratio over 5 years: stood at 23.06 in 2022, then plunged by 59178890.36% to 13648055.74 in 2023, then soared by 100.0% to 15.25 in 2024, then slumped by 76.51% to 3.58 in 2025, then slumped by 352.79% to 9.05 in 2026.
- The last three Interest Coverage Ratio figures came in at 9.05 (Q1 2026), 3.58 (Q4 2025), and 7.71 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 9.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.95 |
| Mar 31, 2026 | -9.05 |
| Dec 31, 2025 | 3.58 |
| Sep 30, 2025 | 7.71 |
| Jun 30, 2025 | -55.74 |
| Mar 31, 2025 | -10.14 |
| Dec 31, 2024 | 15.25 |
| Sep 30, 2024 | 12.78 |
| Jun 30, 2024 | -52.73 |
| Mar 31, 2024 | 32.47 |
| Dec 31, 2023 | -13.65 Mn |
| Sep 30, 2023 | -6.72 |
| Jun 30, 2023 | 10.65 |
| Mar 31, 2023 | 21.09 |
| Dec 31, 2022 | -23.06 |
| Sep 30, 2022 | -15.04 |
| Jun 30, 2022 | -50.75 |
| Mar 31, 2022 | 31.77 |
| Dec 31, 2021 | 147.73 |
| Sep 30, 2021 | 600.76 |